文献速递帕金森病与运动障碍认知障碍与痴呆

进行性核上性麻痹:新诊断标准、生物标志物与治疗进展

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.
PubMed 文献 · Lancet Neurol · 2017-06-13

本文综述进行性核上性麻痹(PSP)作为4重复tau蛋白病相关的一系列运动与行为综合征,介绍了运动障碍学会新诊断标准可识别早期表现并定义变异型PSP综合征,新生物标志物可提高诊断特异性,tau靶向治疗临床试验受关注且可能惠及其他tau蛋白病。

要点

  • PSP是4重复tau蛋白病相关的运动与行为综合征谱系。
  • 运动障碍学会新标准可识别早期PSP及变异型PSP综合征。
  • 新生物标志物联合临床特征可提高PSP病理诊断特异性。

核心结论

  • PSP被认识为与特征性4重复tau神经病理相关的一系列运动与行为综合征。
  • 新诊断标准可识别早期PSP并操作化诊断全谱临床表型。
  • tau靶向治疗可能通过降低毒性tau浓度或补偿tau功能丧失产生疾病修饰效应。

研究设计与样本

  • 本文为综述,依据已报道的新研究标准、诊断生物标志物数据及tau靶向治疗临床试验进展进行汇总。

主要发现

  • 运动障碍学会PSP诊断标准纳入症状轻微但提示潜在PSP病理的综合征,为未来早期治疗干预提供机会。
  • 新标准包含变异型PSP综合征定义,其运动、语言或行为特征模式尚未与PSP病理确证关联。
  • 新诊断生物标志物数据可与临床特征结合,提高新标准对潜在PSP病理诊断的特异性。
  • 因PSP与tau蛋白异常相关,针对新tau靶向治疗的临床试验兴趣日益增长。

关键数值与推荐

  • 运动障碍学会PSP诊断标准纳入症状轻微但提示潜在PSP病理的综合征。
  • 新标准定义变异型PSP综合征,其运动、语言或行为特征模式尚未与PSP病理确证关联。
  • 新诊断生物标志物数据可与临床特征结合以提高诊断特异性。

临床怎么用

  • 临床可应用运动障碍学会新标准识别早期PSP及变异型PSP综合征。
  • 可将新诊断生物标志物与临床特征结合以提高对潜在PSP病理的诊断特异性。
  • tau靶向治疗若在PSP成功,可能为阿尔茨海默病和慢性创伤性脑病等其他tau蛋白病提供治疗借鉴。

局限性

  • 变异型PSP综合征的不同运动、语言或行为特征模式尚未与PSP病理确证关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017. PMID: 28653647. doi:10.1016/S1474-4422(17)30157-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。